Targeting the EGFR with small-molecule inhibitors is a confirmed valid strategy in cancer
therapy. Since the FDA approval of the first EGFR-TKI, erlotinib, great efforts have been …

Breast cancer is one of the most prevalent cancers in women and a leading cause of
mortality. As per the GLOBCAN report of 2021, breast cancer has surpassed lung cancer …

Tyrosine kinase inhibitors (TKIs) are the standard of care for patients with non-small cell lung
cancer (NSCLC) that harbor mutations of the epidermal growth factor receptor (EGFR) gene …

Lung cancer continues to be a malignant tumor with high mortality. Two obstacles interfere
with curative therapy of lung cancer:(i) poor diagnosis at the early stages, as symptoms are …

WNT/β-catenin signaling is a highly complex pathway that plays diverse roles in various
cellular processes. While WNT ligands usually signal through their dedicated Frizzled …

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is currently the
standard first-line therapy for EGFR-mutated advanced non-small cell lung cancer (NSCLC) …

Effectiveness of epidermal growth factor receptor (EGFR) inhibitors, including Osimertinib,
for treating non-small-cell lung cancer (NSCLC) is limited due to the continuous emergence …

The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib has
significantly prolonged progression-free survival (PFS) in patients with EGFR-mutant lung …

Despite the rapid advancement in the introduction of new drugs for cancer therapy, the
frequent emergence of drug resistance leads to disease progression or tumor recurrence …

Dihydropyrimidines are usually synthesized from Biginelli reaction which are well known for
their anti-cancer activity. A series of novel Biginelli-1, 4-dihydropyrimidines are rationally …